Northeastern’s MS in Biotechnology, a certified Professional Master of Science program, is an innovative, non-thesis graduate degree program. It combines advanced interdisciplinary training in biotechnology, biology, chemistry, and pharmaceutical sciences with the development of high-value business skills critical to success in today’s dynamic workplace. Graduates are prepared to innovate, collaborate, and lead as research, managerial, or technical professionals in a wide range of biotechnology specialties.
The MS in Biotechnology is a collaboration between the College of Science and Bouvé College of Health Sciences. Students choose from four concentrations in which core courses are combined with elective study matched with their specialization. All concentrations feature the opportunity to participate in hands-on lab experience, take part in independent work in research labs, and complete a co-op assignment with a leading industry employer. Current program concentrations include:
- Biopharmaceutical Analytical Sciences
- Biotechnology Enterprise
- Pharmaceutical Technologies
- Process Sciences
Certified Professional Science Master’s Program
The Professional Master of Science (PSM) certification is awarded to interdisciplinary graduate degree programs designed to enable students to pursue advanced training and excel in science without a PhD while simultaneously developing professional business knowledge and capabilities without acquiring an MBA. PSM programs are characterized by instruction in advanced science or mathematics, business courses, and a graduate co-op providing a “real world” work experience. Graduates are sought by employers for their deep knowledge of a specific discipline and broad knowledge of the communications and relational skills necessary to excel in any business and adapt to a changing workplace.
Northeastern’s MS in Biotechnology program is taught by respected faculty who are also senior leaders in the field. They bring extensive experience, first-hand knowledge of industry trends, and assure that the curriculum is rigorous, current, and relevant.
Industrial Advisory Board representatives from:
Cyta Therapeutics, Inc.
EMD Serono Research Institute
GlycoFi, , Merck & Co., Inc.
Novartis Institutes of Biomedical Research, Inc.
Takeda Pharmaceuticals International Co.
The program’s exceptional faculty features some of Northeastern University’s renowned experts such as William Hancock, co-chair, Trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk and editor-in-chief of “Journal of Proteome Research” and Jeff Agar, whose lab has developed a technique for metabolic labeling for quantitative MS.